You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
华润医药(03320.HK)旗下华润双鹤收购天东制药38.75%股权
阿思达克 12-18 16:35
华润医药(03320.HK)旗下子公司华润双鹤公布,根据公司整体战略规划,为进一步丰富心脑血管抗凝领域产品、获得抗凝领域技术平台,利用自有资金收购天东制药38.75%的股权,收购价格为3.41亿元。

公司指,投资并购是华润双鹤战略重点举措,尤其在现有存量业务受到带量采购及疫情对诊疗观念影响下,要实现跻身一流制药企业目标,外延并购需大有作为。收购天东制药38.75%的股权,将为双鹤外延式发展提供支援,有利於实现华润双鹤战略目标,有助於华润双鹤成功布局肝素抗凝领域、获得心脑血管抗凝领域不可缺少的药品——肝素(原料药及制剂),对公司规模扩张、产品结构调整、领域布局、研发创新等方面发挥重要作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account